Pulmo BioTech Announces Methodology for Phase I Human Trials
Posted on: Monday, 19 May 2008, 12:00 CDT
Pulmo BioTech has reported details of the methodology and purpose of its Phase I human trials with its PulmoBind molecular imaging technology for the diagnosis of pulmonary embolism and pulmonary hypertension.
The study will be a single center, Phase I safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung disease. It will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc.
The study outcomes will be safety - to determine pharmacokinetics and biodistribution of PulmoBind in humans and to perform dosimetric evaluation, and efficacy - to evaluate the ability of PulmoBind to allow lung perfusion imaging in humans. Pulmo BioTech expects this work to be completed by late summer 2008.
Source: Datamonitor
Related Articles
- Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmonary Ci
- Reportlinker Adds Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
- Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
- Pulmo BioTech Inc. Announces Further Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
- Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM)
- Pulmo BioTech's Subsidiary Completes Bio-Distribution Studies
- Pulmo BioTech Inc. Completes Bio-Distribution Studies
- Pulmo BioTech Inc. Announces Possibility of MRI Application for PulmoBind
- Pulmo BioTech Announces Details of the Methodology for Its Phase I Human Trials
- Environmental and Production Benefits Drive Greater Demand for Biotech Crops
 |
 |
User Comments (0)
RSS Feeds